CBN: The Sleepy Cannabinoid That's Become a $400M Sleep Market

Cannabinol — CBN — has become the cannabis industry’s answer to melatonin. CBN sleep gummies, tinctures, and capsules have flooded the market, with product labels promising “deep, restful sleep” and “nature’s sedative.” The CBN-specific product market reached an estimated $400 million in 2025, driven almost entirely by its reputation as the cannabinoid that makes you sleepy.

There is one problem with this narrative: the clinical evidence that CBN is a sedative is remarkably thin. The entire foundation of the “sleepy cannabinoid” reputation rests on a single 1975 study involving five male subjects — and even that study’s results do not clearly support the claim.

What CBN Actually Is

CBN is a minor cannabinoid formed when THC degrades over time through oxidation and exposure to light and heat. It is not produced directly by the cannabis plant’s biosynthetic pathways. When you find aged cannabis that has been sitting for months or years, the THC has partially converted to CBN. This is why old cannabis is often described as producing a more sedating, less psychoactive experience — but attributing that entirely to CBN oversimplifies a complex chemical process.

CBN has approximately 10% of THC’s binding affinity for CB1 receptors, making it mildly psychoactive but far less intoxicating than THC. It also has moderate affinity for CB2 receptors, suggesting potential anti-inflammatory and immune-modulating properties.

The 1975 Study: What It Actually Found

The study that launched the CBN sleep industry was a 1975 paper by Musty et al., which gave five subjects combinations of THC and CBN in various doses. The finding that generated the sedation claim: subjects who received THC plus CBN reported more drowsiness than those who received THC alone.

Critically, CBN alone — without THC — did not produce significant sedation in this study. The drowsiness increase was observed only in the combination condition. The study was also tiny (five subjects), not placebo-controlled to modern standards, and has not been replicated in 50 years.

Despite this, the cannabis industry built a $400 million product category on the assumption that CBN is inherently sedating.

What Newer Research Shows

More recent studies have produced mixed results. A 2021 review published in the Journal of Cannabis Research concluded that “there is insufficient published evidence to support the claims that CBN is a sedative.” The authors noted that the sedative effects commonly attributed to CBN may actually be due to other compounds present in aged cannabis — particularly terpenes like myrcene and linalool, which have better-documented sedative properties.

A 2022 animal study found that CBN did not produce significant sedation in mice at doses equivalent to those used in consumer products. However, a 2023 human pilot study (also small, 20 participants) reported that CBN improved subjective sleep quality compared to placebo — though objective sleep measurements (polysomnography) were not included.

The honest assessment: CBN may contribute to sleep when combined with other cannabinoids and terpenes, but the evidence that CBN alone is an effective sedative is not established.

Why People Think It Works

If the clinical evidence is weak, why do so many consumers report that CBN products help them sleep? Several explanations:

Placebo effect. Sleep is highly susceptible to placebo effects. Studies consistently show that inert substances labeled as sleep aids improve subjective sleep quality.

Other ingredients. Many CBN sleep products also contain THC, CBD, melatonin, terpenes (myrcene, linalool), or herbal extracts (valerian, chamomile). Any of these could be driving the perceived effect.

The entourage hypothesis. CBN may genuinely contribute to sedation when combined with THC and sedating terpenes, even if it is not sedating on its own. The 1975 study found this exact pattern — CBN enhanced THC’s sedating effects.

Dose-response ambiguity. Most CBN products contain 5mg to 15mg per serving. Clinical trials exploring CBN’s effects have used doses up to 100mg. Consumer products may be below the threshold for pharmacological activity.

What About Other CBN Benefits?

While sleep gets all the marketing attention, preliminary research suggests CBN may have other properties worth investigating:

Appetite stimulation. A 2012 animal study found CBN increased food consumption in rats, suggesting potential application for cachexia and appetite loss.

Antibacterial activity. A 2008 study found CBN showed potent antibacterial activity against MRSA (methicillin-resistant Staphylococcus aureus), though this was an in vitro finding with no human studies.

Anti-inflammatory. CBN’s CB2 receptor affinity suggests anti-inflammatory potential, and some preclinical studies support this — but again, human data is lacking.

The Bottom Line

CBN products are not scams — they may genuinely improve sleep for some users, particularly when combined with other cannabinoids and terpenes. But the marketing has vastly outpaced the science. If you are buying a CBN product specifically for sleep, you should know that the evidence supporting CBN as a standalone sedative is weak. You are likely getting more benefit from the other compounds in the product than from the CBN itself.

If sleep is your goal, products with documented sedating compounds — THC in small doses, linalool, myrcene, or CBD at higher doses — may be more evidence-based choices. And if a CBN product works for you, it works — individual response matters more than population-level clinical trial data. Just understand what you are buying and what the science actually supports.